Browse studies

Find your next paid study

22 recruiting studies matching your filters

Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are exper…

Ovarian CancerOvarian CarcinomaStage II Ovary Cancer+11 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05429970

Phase 2

Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within si…

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more

Estimated

~$10 – $7,500

Ronald BuckanovichNCT05538091

Phase 2

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, f…

Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma+7 more

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC)…

Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+8 more

Estimated

~$10 – $7,500

MacroGenicsNCT06730347

Phase 1

A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy f…

Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06469281

Phase 1

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patien…

Malignant Female Reproductive System NeoplasmRecurrent Cervical CarcinomaRecurrent Endometrial Carcinoma+22 more

Estimated

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researcher…

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+7 more

Estimated

~$10 – $750

University of WashingtonNCT06295965

Phase 2

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab …

Fallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+12 more

Estimated

~$10 – $7,500

Observational

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on phy…

Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+10 more

Estimated

~$10 – $7,500

Roswell Park Cancer Institute

Phase 1

Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer

This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a peri…

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+13 more

Estimated

~$10 – $6,250